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ABSTRACT
It has been shown in vitro that even a small air leak in the facemask can drastically reduce
the efficiency of drug delivery. In addition, it has been shown that drug deposition on the
face does significantly add to overall drug loss and has the potential of local side effects. The
aim of this study is therefore to verify these findings in vivo. Eight asymptomatic recurrently
wheezy children, aged 18–36 months, inhaled a radiolabeled salbutamol formulation either
from a pressurized metered-dose inhaler through a spacer with attached facemask or from a
nebulizer with attached facemask. Drug deposition of radiolabeled salbutamol was assessed
with a gamma camera and expressed as a percentage of the total dose. Lung deposition ex-
pressed as a percentage of the total dose (metered dose and nebulizer fill, respectively) was
0.2% and 0.3% in children who inhaled with a non-tightly fitted facemask. Lung deposition
was 0.6% and 1.4% in screaming children with a tightly fitted facemask and between 4.8%
and 8.2% in patients breathing normally. Overall mask deposition was between 0.8% and
5.2%. Overall face deposition was between 2.6% and 8.4%. The results from this pilot study
support the results found in in vitro studies, where a facemask leak greatly reduces drug de-
livery to the patient.




YOUNG CHILDREN, generally under the age of 3years, are not able to use a mouthpiece for in-
halation therapy and therefore, they inhale
through a facemask using various delivery de-
vices, such as pressurized metered-dose inhalers
(pMDIs) with spacer or nebulizers. There are sev-
eral in vitro studies which have looked at the ef-
fect of a facemask leak on aerosol delivery.(1–5) A
50% and 80% reduction in drug delivery were
found when the mask of a nebulizer was removed
1 and 2 cm, respectively, from the face.(2) This
finding is true for both pMDI with spacer and
nebulizer.(4) It has also been shown, that even 
a small air leak in the facemask of a pMDI–
spacer–facemask combination can drastically re-
duce the efficiency of drug delivery.(5) In addi-
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tion it has been shown that the efficiency of drug
delivery can be improved using a round facemask
with a flexible rim.(6)
The question arises whether in vivo results mir-
ror in vitro results. There are no in vivo deposition
studies that have looked specifically at the effect
of facemask leaks. On the contrary, in the few per-
formed radiolabeled aerosol deposition studies in
this age group, measures were undertaken to
avoid facemask leaks, mainly by fitting the face-
mask tightly on the child’s face and by putting
vaseline around the facemask rim to ensure a
complete seal.(7–9) In a study using the Ae-
rochamber spacer with corresponding facemask
in 15 infants and young children from 3 months
to 5 years of age the mean deposition of radiola-
beled salbutamol was 1.97% in the lungs, 1.28%
in the oropharynx and 1.11% in the stomach.(7)
Using a non-electrostatic spacer (detergent
washed Babyhaler spacer with corresponding
facemask) lung deposition has been shown to be
much higher (16.4%).(8) In a comparison of ra-
diolabeled salbutamol delivery lung deposition
has been shown to be similar through the Aero-
chamber spacer with corresponding facemask
and through a nebulizer with a Pari baby face-
mask.(9) In this study, it has been shown that the
amount of drug deposited in the mask is rela-
tively small and varies between the two masks
used, with a mean (SD) facemask deposition of
2.4% (1.8) for the Pari baby facemask and 4.5%
(2.1) for the Aerochamber mask. A dramatic re-
duction of drug delivery has been reported when
the facemask was not tightly fitted to the face.(10)
Drug deposition on the face has generally been
included in overall oropharyngeal deposition and
has never been calculated separately. However,
by visualizing scintigraphic pictures, it is clearly
depicted that a significant portion of the drug is
deposited on the face outlined by the shape of the
mask used. The aim of this pilot study was to an-
alyze face drug deposition from young children
using a pMDI/spacer combination or a nebulizer,




In vivo lung deposition was studied in eight
asymptomatic, recurrently wheezy children (five
boys) aged 18–36 months (a: 26 months, b: 28
months, c: 20 months, d: 24 months, e: 31 months,
f: 18 months, g: 26 months, and h: 36 months of
age, respectively). Written informed consent was
obtained from all parents, and the study was ap-
proved by the local hospital ethics committee.
Study design
The children inhaled technetium99 (Tc99)–ra-
diolabelled salbutamol (Ventolin, Allen Han-
burys, Sydney, Australia). Four children inhaled
2 mL of radiolabeled salbutamol solution (Ven-
tolin, 1 mg/mL, Allen Hanburys, Sydney, Aus-
tralia) from an open vent-assisted nebulizer (Pari
Baby with Pari facemask no. 2) driven by a com-
pressor (Pari Proneb Turbo, Pari Boy type 38).
Four children inhaled four puffs from a radio-
labeled salbutamol pMDI (Ventolin, 100 g/
actuation; Allen Hanburys, Sydney, Australia)
through a plastic holding chamber (Aerochamber
with an Aerochamber 2cd generation face mask;
Trudell Medical, Hamilton, Canada). To ensure a
tightly fitting face mask, the rim of the mask was
covered with vaseline. In two infants, a seal could
not be achieved due to the lack of cooperation.
The dose in the nebulizer was quantified be-
fore, and the dose in the pMDI canister was quan-
tified before and after the inhalation procedure
with an ionization chamber (Atomlab 200 dose
calibrator; Gammasonics, Sydney, NSW, Aus-
tralia). The dose of Tc99 to be given to each pa-
tient was assessed before the inhalation proce-
dure was performed, so that patients would not
receive a dose exceeding 2 MBq in total dose. All
patients inhaled tidally through the nebulizer for
5 min and were allowed five tidal breaths be-
tween each actuation of the pMDI. The pMDI 
was shaken between actuations. A filter (Curity
Anaesthesia Filter, Kendall, MA) was inserted at
the expiratory valves of both the nebulizer and
the holding chamber to collect the expired
aerosol.
Quantification of the distribution of activity de-
positing in the patients was done in the follow-
ing way. A flood source containing approxi-
mately 37 MBq Tc99 was used to obtain values for
attenuation of activity caused by absorption by
body tissues. Because attenuation of activity is de-
pendent on size and body mass, and these para-
meters varied greatly between patients, an atten-
uation value was determined for each patient and
each region of interest. After the inhalation pro-
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cedure was performed, anterior and posterior im-
ages of the chest and the abdomen were obtained
with lateral images of the upper airway with a
gamma camera (Dual Head GCA-7200A; Toshiba
Corp., Tochigi-Ken, Japan). Collection times were
2 min for each of the images. Areas of interest
were defined for each of the images, and separate
count rates were determined for the right and left
lungs, stomach, esophagus, throat, mouth, and
face. Each count rate was corrected for back-
ground counts and attenuation, and the geomet-
ric means of corresponding anterior and poste-
rior count rates were calculated. For the
nebulizer, the dose deposited in the lungs was
then expressed as a percentage of the total nebu-
lizer fill dose. For the pMDI and spacer, the dose
deposited in the lungs was expressed as a per-
centage of the total metered dose. Gastrointesti-
nal deposition was defined as the total dose de-
posited in the mouth, throat, esophagus and
stomach. The ratio face/lung deposition was de-
fined as therapeutic index.
Labeling of salbutamol
Nebulizer solution. A total of 15 MBq of Tc99
bound to diethylenetriamine penta-acetic acid
was added to 2 mL of salbutamol solution. The
droplet spectrum from the nebulizer was mea-
sured with a laser particle sizer (Master Sizer X
Version 1.2a; Malvern Instruments GmbH,
Herrsching, Germany).
Salbutamol pMDI. For the labeling of a canister,
500–600 MBq Tc99 (0.5–1.0 mL) was eluted from
a generator (Technetium 99m Generator; Aus-
tralian Radioisotopes, Lucas Heights, NSW, Aus-
tralia) and made up to 2 mL with 20% NaCl. The
2 mL was then poured into a separating funnel
and shaken together with 4 mL of ethyl methyl
ketone (butanone). The two phases were allowed
to separate, and the top layer (Tc99 in butanone)
was collected in a new pMDI canister. The col-
lected butanone containing the radioactivity was
evaporated for 12 min in a nitrogen flow (9–13 
L  min1). The canister was placed into an oven
for half an hour at a temperature of 73–85°C to
evaporate the water content. The canister was
then placed in dry ice to be cooled. A frozen (dry
ice) commercial pMDI was opened with a pipe
cutter (TC1000, Imperial Eastman), and the con-
tent was poured into the cooled canister contain-
ing the radioactivity and immediately crimped
(Crimper Type 555G, Pamasol; Willi Mäder AG,
Pfäffikon, Switzerland). The closed canister was
subsequently shaken for half an hour. In vitro as-
sessment of radiolabeling was done by measur-
ing in vitro particle size distribution and total
drug delivery with a multistage liquid impinger
(MSLI; Copley, Nottingham, UK) before and af-
ter the children were tested. The sizes of particles
deposited on stages 1, 2, 3, and 4 were 13 m,
6.8–13 m, 3.1–6.8 m, and 3.1 m, respec-
tively. Ten actuations of radiolabeled salbutamol
from the pMDI were drawn through the MSLI at
a continuous flow of 60 L  min1. The actuator,
the glass throat, and the four stages of the MSLI
were washed with 45 mL of methanol. A total of
5 mL of 0.1 mol/L NaOH was added to each
wash. The absorbance of salbutamol (wavelength
246 nm) was measured in each wash with a spec-
trophotometric method. The concentration of
salbutamol was calculated with the absorbance of
a solution containing a known concentration of
salbutamol. The standard curve for salbutamol
was linear (r2  1.00) for concentrations between
0 and 21 g. The distribution of radioactivity in
the different washes was measured in an ioniza-
tion chamber (Atomlab 200 dose calibrator; Gam-
masonics, Sydney, NSW, Australia). The output
and the particle size distribution of Tc99-labeled
salbutamol from the study pMDIs (n  4) were
then compared with the particle size distribution
of salbutamol from commercial Ventolin pMDIs
(n  4). This comparison was done to confirm
that 99mTc acts as a suitable marker for salbuta-
mol.
RESULTS
There was a good correlation between label
and drug delivery from the pMDI with the fol-
lowing mean (SD) output of particles of 6.8 m
expressed as a percentage of the total metered
dose: 47.8 (3.2), 48.9 (4.1), and 47.6 (2.8) for unla-
beled drug, labeled drug, and radiolabeled drug,
respectively. Radiolabeled drug deposition for
each patient is shown in Table 1 and Figure 1.
Lung deposition expressed as a percentage of the
total dose was 0.2% and 0.3% in children who in-
haled with a non-tightly fitted facemask (leak; pa-
tients a and b). The deposition was 0.6% and 1.4%
in screaming children with a tightly fitted face-
mask (screaming; patients c and d) and between
4.8% and 8.2% in patients quietly inhaling (qui-
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TABLE 1. DRUG DEPOSITION IN YOUNG CHILDREN
Deposition
Age/sex/device Lung Gastrointestinal Mask Face Ratio (face/patient) Ratio (face/lung)
Facemask leak:
(a) 26; m; pMDI 0.2 5.8 1.2 2.6 0.4 13
(b) 28; m; nebulizer 0.3 4.7 2.4 3.1 0.6 10
No facemask leak, screaming:
(c) 20; f; pMDI 0.6 15.8 5.2 7.9 0.5 13
(d) 24; m; nebulizer 1.4 19.7 0.9 8.4 0.4 6
No facemask leak, quietly inhaling:
(e) 31 m; pMDI 7.4 12.2 4.4 5.2 0.3 0.7
(f) 18; f; pMDI 5.2 13.8 3.2 7.8 0.4 1.5
(g) 26; f; nebulizer 4.8 9.3 1.8 4.8 0.3 1
(h) 36; m; nebulizer 8.2 10.1 0.8 3.6 0.1 0.4
Drug deposition expressed as a percentage of the total dose in a young child: (a) inhaling with a pMDI/spacer
through a non-tightly fitted face mask, (b) inhaling with a nebulizer through a non-tightly fitting face mask, (c) in-
haling with a pMDI/spacer through a tightly fitted face mask, screaming during inhalation, (d) inhaling with a neb-
ulizer through a tightly fitted face mask, screaming during inhalation, (e and f) inhaling with a pMDI/spacer through
a tightly fitted face mask, quietly inhaling, and (g and h) inhaling from a nebulizer through a tightly fitted face mask
quietly inhaling.
FIG. 1. Drug deposition of radiolabeled Salbutamol in a young child (A) inhaling with a pMDI/spacer through a
non-tightly fitted facemask, (B) inhaling with a nebulizer through a non-tightly fitted facemask, (C) inhaling with a
pMDI/spacer through a tightly fitted facemask, screaming during inhalation, (D) inhaling with a nebulizer through
a tightly fitted facemask, screaming during inhalation, (E,F) inhaling with a pMDI/spacer through a tightly fitted
facemask, quietly inhaling, and (G,H) inhaling from a nebulizer through a tightly fitted facemask, quietly inhaling.
etly inhaling; patients e, f, g, and h). Mask depo-
sition was between 0.8% and 5.2%. Face deposi-
tion was between 2.6% and 8.4%. The ratio
face/patient deposition and especially the ratio
face/lung deposition as a measure of therapeutic
index were much higher in quietly inhaling chil-
dren.
DISCUSSION
Our in vivo pilot study in children inhaling with
a facemask supports the results found in in vitro
studies, where a facemask leak greatly reduces
drug delivery to the patient.(1–6) In addition, face
drug deposition is significant. In comparison to a
mask leak and face deposition, the deposition in
the mask is of a lesser impact on overall drug loss.
The aim of an inhaled therapy is to effectively
deliver drug to its site of action. The administra-
tion of aerosolized drug to children in general
and to young children in particular has been
shown to be difficult with only a very small
amount of drug reaching the airways.(11) This
may be partly explained by the age specific
breathing patterns as well as airway anatomy. It
has been shown that lung deposition could be
greatly improved when these parameters are
taken into account.(10,12,13) However, lung depo-
sition in young children has been shown to be
low, mainly due to drug loss in the device itself
(nebulizer and spacer).(11) Drug loss in general re-
duces the drug available at the site of action. Sur-
prisingly, there is not much in vivo data on the in-
fluence of a facemask on overall drug deposition.
A facemask is not easily accepted by young chil-
dren and screaming during inhalation reduces
parental compliance.(14)
It has been shown in vitro that the inhaled mass
from a nebulizer with facemask is low with a high
facial drug deposition and a variable eye drug
deposition, where the eyes seem to be a focal
point of deposition.(15) Our in vivo data suggest a
higher face deposition than found in vitro. Sag-
wan et al. found a facial deposition at 0.44–2.34%
of nebulizer charge, with eye deposition at
0.09–1.78%.(15) This difference may be explained
by the different surface proprieties, where the
skin may attract more aerosols than the surface
of the in vitro model. Another explanation may
be that in in vivo studies using two dimensional
scintigraphy there could be some overlap with
mouth deposition and hence, an overestimation
of facial drug deposition. A tight seal was
achieved in the present in vivo studies by putting
vaseline around the mask rim. Therefore we
could not reproduce the finding of focal eye de-
position from in vitro results. Looking at the
scintigraphy pictures of patient a and b, inhaling
with a non-tightly fitted facemask, there seems to
be a focal eye deposition. We could therefore il-
lustrate in these two non-cooperative young chil-
dren, that a facemask leak greatly reduces depo-
sition within the patient.
Drug loss in general reduces the drug available
at the site of action. Therefore, it is crucial to im-
prove the interface between the device and the
patient in general and the facemask in particu-
lar.(17) In addition, face drug deposition bears the
potential of local side effects. Some data from the
literature suggests that local side effects are min-
imal.(16,17) On the other hand, there is a study that
has shown local side-effects of inhaled corticos-
teroids to be common in asthmatic children of all
ages, and that the device used constitutes the
most influential factor.(18)
In summary, a facemask should have an effec-
tive seal, be flexible and soft with a large inward
curved rim and have a minimal dead space. De-
spite these technical considerations, patient coop-
eration remains the main limiting factor in aerosol
therapy in young children. It would be useful to
have more data on in vivo aerosol deposition from
various devices using various facemasks, to assess
the influence of mask design on drug deposition
in general and on face deposition in particular.
These insights would inturn lead to optimal in-
halation therapy in young children.
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Beth Laube, Ph.D.: I’d like to ask a technical ques-
tion: In your images, how do you differentiate be-
tween the mask and the face in a lateral view?
Johannes Wildhaber, M.D., Ph.D.: We don’t im-
age the mask while it’s on the face. It’s looked at
separately. And because the view is only two-di-
mensional, and there is an overlap, I really can’t
properly account for the patterns of deposition;
there may be some oral or nasal deposition. That
is a problem, but I don’t think it influences the
results.
Dr. Laube: Then particle deposition on the mask
is counted separately?
Dr. Wildhaber: Yes.
Gerald Smaldone, M.D., Ph.D.: I’m seeing these
data for the first time, but I’d suggest that we have
to think about mechanism, particularly with the
Pari baby E-Flow mask, to take but one example.
If you use a Vaseline seal and a low-pressure sys-
tem, I’d think that there is probably some type 
of flow regime in the mask during expiration
whereby the aerosol particles are depositing on
the face.
I also wanted to say that in the experiments with
the metered dose inhaler (MDI), I was struck by
the amount of aerosol that seemed to be deposited
in the facial region, which I wouldn’t have ex-
pected solely on the basis of what we know right
now about MDIs. I haven’t looked at particle de-
position in the eyes of infants with the use of ra-
diolabeled particles, but I would think that in a
system that is not highly pressurized, the child’s
breathing is pressurizing the mask, and they may
be exhaling particles so as to create the milieu for
facial deposition and deposition on the mask dur-
ing breathing. I think your data are very chal-
lenging, but very important, and create a whole
new conceptual area because much of the data
were not produced with pressurized nebulizers.
Dr. Wildhaber: I will look back and analyze all
the data I have. On the basis of simple visualiza-
tion, though, the data don’t look that different. I
also thought about the E-Flow mask and the
rather low particle output with it in the test, but
I’m not sure whether that has an impact. The low
flow may influence facial deposition, but I’m not
sure that that was the responsible mechanism. Be-
sides this, I was surprised because I expected
hardly any facial deposition with the pressurized
MDI (pMDI) spacers, and was struck by the
amount of aerosol that was deposited on the face
with them. I have no explanation for those find-
ings.
Chris O’Callaghan, FRCP, FRCPCH, D.M.,
Ph.D.: We would very much like to undertake
one or two aerosol deposition studies in children.
We think that it’s very important to determine
where an aerosol drug is deposited, because of
the therapeutically specific nature of these drugs.
Our problem has been in getting ethical approval
for studies of this. The factor acting against us is
the need for informed consent by parents, who
argue that an inhaled radioactive drug may go
into their child’s lungs and be preferentially de-
posited at airway bifurcations, which will create
radioactive “hot spots” on the affected groups of
cells. How can you tell the specific dose of ra-
dioactivity being delivered to individual cells? As
a result, we have to say that we don’t know the
dose your child is getting at specific cell sites, but
please sign here to indicate that you approve our
study. And that is making it difficult for us to do
some of the studies we’d like to do.
Dr. Wildhaber: That was exactly the same argu-
ment that our ethical committee had, and as a re-
sult I can’t do such studies in Zurich, either.
Mitchell A. Baran: Dr. Wildhaber, did you by any
chance compare your results with the 3-month to
5-year-old group (mean age, 21 months) with the
results that Asher Tal and colleagues evaluated a
number of years ago, some of whom had cystic
fibrosis?
Dr. Wildhaber: That’s the group I showed. It
seemed that, visually, their results looked quite
similar to ours, but I can’t analyze them because
you need the full data to do that.
Mr. Baran: Yes, the data for your birth to 24-
month-old group looked quite similar to the data
of Asher, Tal, and colleagues with the Aero-
Chamber® valved holding chamber, despite the
fact that they were physically impaired with cys-
tic fibrosis lung disease.
Hettie Janssens, M.D., Ph.D.: It’s nice to have a
new look at your old data, although I think it is
surprising that there is such a substantial depo-
sition on the face. But if I am a bit provocative, I
can ask you, “Who cares?” Does it matter if you
lose a lot of medication on the face?
Dr. Wildhaber: What you want is to get the drug
into the lungs. You don’t want to have it on the
face. So the issue has to do with efficiency. Ob-
viously, we have to think about side effects when
we increase the extraneous deposition, but pri-
marily we want to get the drug into the lungs,
and that’s really why the facial deposition mat-
ters. And I was surprised how significant the fa-
cial deposition was.
Dr. Janssens: But you can also do something
about it.
Dr. Wildhaber: That was my approach as well.
Clearly, you can just wash off that deposition, but
now, in looking at the data, I realize it’s a signif-
icant component of overall deposition.
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